“American competitiveness in science and innovation relies, to a great extent, on the development and production of key isotopes, and Serva is proud to support this mission,” said Ian Horvath, Serva’s founder and CEO, in response to the recent U.S. investment in isotope production and research.
Last month, U.S. Secretary of Energy Jennifer M. Granholm spoke at a groundbreaking ceremony for the U.S. Stable Isotope Production and Research Center—a new facility aimed at bolstering the United States’ capability “to enrich stable isotopes for medical, industrial, and research applications.”
The U.S. Department of Energy also announced $75 million in funding, provided through President Biden’s Inflation Reduction Act, to support the center.
“Isotopes are essential to helping diagnose and treat diseases like cancer and for identifying nuclear threats,” said Secretary Granholm. “With support from the President’s Inflation Reduction Act, the world-class Stable Isotope Production and Research Center will help establish a reliable domestic supply of isotopes critical to the health and safety of Americans in every corner of the nation.”
While isotopes are indispensable to the growth of our economy—impacting everything from medicine to renewable energy— the United States remains vulnerable to unstable foreign supply chains and chronic shortages, which have limited the use of existing radiopharmaceuticals and hampered innovation.
Helping to diminish national risk, Serva Energy is working with the National Isotope Development Center to meet the growing global and domestic demand for isotopes, increasingly used in the health care and clean energy sectors.
“Helping build a safe and reliable domestic supply chain for these materials is a big part of our mission at Serva," said Horvath, "where we are hyper-focused on developing next-generation nuclear technologies that will serve the greater patient population and the climate solutions we so direly need.”
Comments